Should I buy or sell Rigel Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RIGL shares. View RIGL analyst ratings or view top-rated stocks .

What is Rigel Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price targets for Rigel Pharmaceuticals' shares. Their RIGL share price targets range from $1.25 to $15.00. On average, they anticipate the company's share price to reach $5.81 in the next twelve months. This suggests a possible upside of 423.6% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts .

How have RIGL shares performed in 2024?

Rigel Pharmaceuticals' stock was trading at $1.45 at the beginning of the year. Since then, RIGL stock has decreased by 23.4% and is now trading at $1.11. View the best growth stocks for 2024 here .

When is Rigel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RIGL earnings forecast .

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. The biotechnology company had revenue of $28.13 million for the quarter, compared to analysts' expectations of $27.83 million. During the same period in the prior year, the company posted ($0.11) EPS.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com . Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Sorrento Therapeutics (SRNE) , Aeterna Zentaris (AEZS) , KushCo (KSHB) , Novan (NOVN) , Bionano Genomics (BNGO) , Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI) .

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.34%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends .

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free RIGL Stock Alerts

$1.11

-0.03 (-2.63%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.11
▼
$1.16
50-Day Range: $1.11
▼
$1.57
52-Week Range: $0.71
▼
$1.96

Volume: 578,019 shs
Average Volume: 1.24 million shs
Market Capitalization: $194.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.81

Get Rigel Pharmaceuticals alerts:

Rigel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 423.6% Upside
$5.81 Price Target
Short Interest: Bearish
2.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.05) to $0.05 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.64 out of 5 stars

Medical Sector

703rd out of 913 stocks

Pharmaceutical Preparations Industry

307th out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
Rigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Rigel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.86% of the outstanding shares of Rigel Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Rigel Pharmaceuticals has recently increased by 1.42%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rigel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rigel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RIGL.

2.5

News and Social Media Coverage

News Sentiment
Rigel Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.43% of the stock of Rigel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.05) to $0.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rigel Pharmaceuticals is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rigel Pharmaceuticals is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RIGL Stock News Headlines

April 12, 2024 | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Cross Above 200-Day Moving Average of $1.19

April 10, 2024 | prnewswire.com

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 4, 2024 | prnewswire.com

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

March 16, 2024 | finance.yahoo.com

RIGL Apr 2024 3.000 call

March 12, 2024 | finanznachrichten.de

Rigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

March 12, 2024 | markets.businessinsider.com

Rigel Pharma Names Rojkjaer EVP, Chief Medical Officer

March 12, 2024 | prnewswire.com

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

April 17, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 7, 2024 | finance.yahoo.com

Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year

March 7, 2024 | insidermonkey.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript

March 6, 2024 | barrons.com

Rigel Pharmaceuticals Inc.

March 6, 2024 | stockhouse.com

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 6, 2024 | benzinga.com

Rigel Pharmaceuticals: Q4 Earnings Insights

March 6, 2024 | markets.businessinsider.com

Rigel Pharmaceuticals Inc. Q4 Earnings Summary

March 6, 2024 | msn.com

Rigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39M

March 6, 2024 | finance.yahoo.com

Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),

March 6, 2024 | finance.yahoo.com

Q4 2023 Rigel Pharmaceuticals Inc Earnings Call

March 6, 2024 | gurufocus.com

Q4 2023 Rigel Pharmaceuticals Inc Earnings Call Transcript

March 5, 2024 | investorplace.com

RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023

February 27, 2024 | prnewswire.com

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 26, 2024 | seekingalpha.com

Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects

February 23, 2024 | markets.businessinsider.com

Buy Rating for Rigel: Strategic Acquisitions and Market Positioning Fuel Revenue Growth Potential

February 23, 2024 | finance.yahoo.com

RIGL Mar 2024 1.500 put

February 22, 2024 | benzinga.com

Rigel Pharmaceuticals Stock (NASDAQ:RIGL), Short Interest Report

February 22, 2024 | markets.businessinsider.com

Rigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Market

February 22, 2024 | finance.yahoo.com

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

See More Headlines

Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:RIGL
CUSIP: 76655960
CIK: 1034842
Web: www.rigel.com
Phone: (650) 624-1100
Fax: 650-624-1101
Employees: 147
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $5.81
High Stock Price Target: $15.00
Low Stock Price Target: $1.25
Potential Upside/Downside: +421.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,090,000.00
Net Margins: -21.47%
Pretax Margin: -21.47%
Return on Equity: N/A
Return on Assets: -21.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.86
Quick Ratio: 1.76

Sales & Book Value

Annual Sales: $116.88 million
Price / Sales: 1.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.16) per share
Price / Book: -6.97

Miscellaneous

Outstanding Shares: 175,400,000
Free Float: 164,126,000
Market Cap: $195.57 million
Optionable: Optionable
Beta: 0.95

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Raul R. Rodriguez (Age 63)
President, CEO & Director
Comp: $1.09M
Mr. Dean L. Schorno CPA (Age 61)
Executive VP & CFO
Comp: $696.67k
Mr. Raymond J. Furey J.D. (Age 56)
Executive VP, General Counsel & Corporate Secretary
Comp: $593.46k
Mr. David A. Santos (Age 61)
Executive VP & Chief Commercial Officer
Comp: $681.63k
Ms. Julie Patel
Senior VP of Human Resources
Dr. Esteban S. Masuda (Age 62)
Executive Vice President of Research
Comp: $537.21k
Mr. Joseph Lasaga (Age 49)
Executive VP & Chief Business Officer
Dr. Lisa Rojkjaer M.D. (Age 58)
Executive VP & Chief Medical Officer
Mr. Tarek Sallam
Vice President of Marketing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RIGL shares.
View RIGL analyst ratings or view top-rated stocks.
What is Rigel Pharmaceuticals' stock price target for 2024?: 4 Wall Street research analysts have issued 12-month price targets for Rigel Pharmaceuticals' shares. Their RIGL share price targets range from $1.25 to $15.00. On average, they anticipate the company's share price to reach $5.81 in the next twelve months. This suggests a possible upside of 423.6% from the stock's current price.
View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.
How have RIGL shares performed in 2024?: Rigel Pharmaceuticals' stock was trading at $1.45 at the beginning of the year. Since then, RIGL stock has decreased by 23.4% and is now trading at $1.11.
View the best growth stocks for 2024 here.
When is Rigel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our RIGL earnings forecast.
How were Rigel Pharmaceuticals' earnings last quarter?: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. The biotechnology company had revenue of $28.13 million for the quarter, compared to analysts' expectations of $27.83 million. During the same period in the prior year, the company posted ($0.11) EPS.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?: 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.
What other stocks do shareholders of Rigel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).
Who are Rigel Pharmaceuticals' major shareholders?: Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.34%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez.
View institutional ownership trends.
How do I buy shares of Rigel Pharmaceuticals?: Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RIGL) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial